Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease

Kerry A. Ryan,Shirley Cohen-Mekelburg,Jessica A. Baker,Eileen M. Weinheimer-Haus,Chris Krenz,Jason K. Hou,Raymond De Vries,Akbar K. Waljee

DOI: https://doi.org/10.1186/s12913-024-11570-3

2024-10-11

BMC Health Services Research

Abstract:Biosimilars are highly similar, but not identical, versions of originator biologic medications. Switching patients to biosimilars presents an opportunity to mitigate rising drug costs and expand patient access to important biologic therapies. However, decreased patient acceptance and adherence to biosimilar medications have been reported, which can lead to loss of treatment response, adverse reactions, and inefficient resource utilization. Understanding patient perceptions of biosimilars and biosimilar switching is needed to inform patient-centered care strategies that promote efficient resource utilization.

health care sciences & services